New Provenge Clinical Trial

Clinical trial - NO placebo:Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Currently recruiting in Denver, Seattle, and Virginia Beach.  Contact info in link above.

Basic Eligibility Criteria:

• Metastasis on Bone Scan or CT within 28 days before starting trial
• PSA 2.0 or greater
• Testosterone less than or equal to 50
• Evidence of cancer progression
• NO metastases to lung, liver, or brain
• NO Xgeva (denosumab) within the last 3 months
• NO treatment within the last 28 days with ANY of the following:
  • Proscar
  • Avodart
  • saw palmetto
  • DES
  • Megace
  • Casodex or Eulexin or Nilutamide
  • ketoconazole

 

This trial would give Zytiga (abiraterone) access for free to men who have NOT had chemo. Also access to PROVENGE no matter what your insurance policy is.  Print and discuss with your physician(s).

Hope this helps someone,

 

Jan Manarite
PCRI Senior Educational Facilitator

(310) 743-2110  or(239) 395-0995  DirectThe PROSTATE CANCER RESEARCH INSTITUTE is a registered non-profit organization. Visit us at www.PCRI.org
I am a prostate cancer researcher and advocate, not a medical professional. Information I share with you is to help expand your knowledge for discussion with your own physicians
and should not be considered actual medical advice.

Hi to All,

This trial looks promising.

Dick Gillespie 703/497-0628 

=